Clinical Trials Browser

Phase 2 × Active not recruiting × Paclitaxel × Clear all

NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Phase 2 Active not recruiting

Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

HER2-positive Breast Cancer

NCT04858269 2026-05-22

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04175912 2026-05-20

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Phase 2 Active not recruiting

40 enrolled 11 charts

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT06378177 2026-05-19

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04001829 2026-05-15

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Phase 2 Active not recruiting

249 enrolled 14 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT06251973 2026-05-15

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT05554341 2026-05-14

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT06946797 2026-05-14

CheckMate-1533

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT01081951 2026-05-13

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Phase 2 Active not recruiting

162 enrolled 15 charts

Ovarian Neoplasms

NCT04090398 2026-05-13

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Phase 2 Active not recruiting

BreastOther neoplasm

Anatomic Stage IV Breast Cancer AJCC v8

NCT04274426 2026-05-13

MIROVA

Phase 2 Active not recruiting

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

NCT04310007 2026-05-13

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Phase 2 Active not recruiting

Lung Neoplasms

NCT05775289 2026-05-13

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

182 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung

NCT03609047 2026-05-12

Appalaches

Phase 2 Active not recruiting

Breast Neoplasms

NCT05498896 2026-05-08

BARBICAN

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Active not recruiting

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT04266249 2026-05-05

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Phase 2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT05012254 2026-05-05

NIVIPI-Brain

Phase 2 Active not recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT05684276 2026-05-05

DUMAS

Phase 2 Active not recruiting

Pancoast Syndrome

NCT04736173 2026-05-01

ARC-10

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03838159 2026-04-30

NADIMII

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT00977574 2026-04-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

349 enrolled 11 charts

GynecologicSarcoma

Endometrial Adenocarcinoma

NCT01142388 2026-04-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Phase 2 Active not recruiting

94 enrolled 8 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06143748 2026-04-23

EC-CRT-006

Phase 2 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02957968 2026-04-21

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06449209 2026-04-17

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05635708 2026-04-15

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT01244789 2026-04-13

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03587311 2026-04-13

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Endometrioid Adenocarcinoma

NCT03965689 2026-04-13

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

Phase 2 Active not recruiting

27 enrolled 13 charts

Lung Neoplasms

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2 Active not recruiting

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT06604858 2026-04-07

TELESCOPE

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05605535 2026-04-01

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02905591 2026-03-25

XACT-LUNG

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT06332092 2026-03-16

HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04293393 2026-03-12

CARABELA

Phase 2 Active not recruiting

200 enrolled 27 charts

Breast Neoplasms

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT06194448 2026-03-06

NEOLA

Phase 2 Active not recruiting

Lung Neoplasms

NCT05247684 2026-03-05

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Phase 2 Active not recruiting

Resectable Non-small Cell Lung Cancer

NCT06727565 2026-03-02

VELOCITY-HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07421141 2026-02-27

Opti-HER2

Phase 2 Active not recruiting

Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03965468 2026-02-09

CHESS

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung